This is an automatically translated article.
Vastarel MR 35mg belongs to the group of cardiovascular drugs and is manufactured by Pymepharco Vietnam Joint Stock Company. It has the active ingredient trimetazidine dihydrochloride and is used in adults for the symptomatic treatment of stable angina pectoris that is inadequately controlled or intolerant of other angina therapies.
1. Indications to use Vaspycar MR 35mg
Vastarel MR 35mg is indicated for use in the following cases:
Treatment and prevention of angina attacks in ischemic heart disease. Treatment and support symptoms of dizziness and tinnitus. Treatment of amblyopia and visual disturbances of circulatory origin.
2. Dosage and how to use Vaspycar MR
How to use
Vaspycar MR is taken orally. Take with 1 glass of water with meals.
Dosage
Dosage is 1 tablet of 35mg trimetazidine, 2 times morning and evening, should be taken with meals. With 20mg tablets: the usual dose is 1 tablet/time, 3 times a day with meals. Patients with moderate renal impairment: the recommended dose is 1 tablet 35mg/day, in the morning, with breakfast. Elderly patients: the recommended dose is 1 tablet 35mg/day, in the morning, with breakfast. Care should be taken when calculating the dose of trimetazidine in elderly patients. Children: The safety and efficacy of trimetazidine in children under 18 years of age have not been evaluated. Therefore, caution should be exercised when prescribing this dose. Patients should take the drug for about 3 months of treatment, if the condition does not improve, the trimetazidine should be stopped.
The above dose of trimetazidine is for reference only. Dosage will depend on the condition and severity of the disease. To get the right dose, the patient should consult a doctor or medical professional.
3. Contraindications to using Vaspycar MR 35mg
Vastarel MR drug should not be used in the following cases:
Hypersensitivity or history of allergy to Trimetazidine or any of its ingredients. Patients with or with symptoms of Parkinson's disease, tremor, restless legs syndrome and other movement disorders. The patient has severe renal failure. Do not use Trimetazidine during lactation.
4. Vaspycar MR interaction with other drugs
Currently, there are no reports of Trimetazidine interactions with any drugs. However, patients still need to be carefully monitored when combined with other drugs.
To avoid possible drug interactions between drugs, the patient should inform the doctor or pharmacist if the patient is currently being treated with any other medication.
5. Side effects when using Vaspycar MR 35mg
When using Vastarel MR, patients may experience undesirable effects such as:
Tremor, spasticity, difficulty in movement Digestive disorders Dizziness, headache, abdominal pain, Diarrhea, Vomiting, nausea Muscle weakness Palpitations Suspense Heart palpitations Extrasystoles Arterial hypertension Orthostatic hypotension Parkinson's symptoms Unsteady gait Sleep disturbance Pustular rash Thrombocytopenia Agranulocytosis Thrombocytopenia purpura Inflammation liver Tell the doctor if the patient experiences any undesirable effects related to taking the medicine.
6. Precautions when using Vaspycar MR
Before using the drug, the patient should carefully read the instructions for use and refer to the information below.
Do not use Vaspycar MR in patients with ongoing chest pain or for the initial treatment of unstable angina. When the patient develops angina, notify the doctor immediately so that tests can be done and the patient's treatment regimen may need to be changed. Trimetazidine is not used to treat myocardial infarction. Do not use in patients with hypersensitivity to the active ingredient or to any of the excipients listed in the product formulation. Patients suffering from or having symptoms of Parkinson's disease, restless legs syndrome, tremors, movement disorders, etc. should not use the drug. Trimetazidine dihydrochloride should be used with caution in patients with severe renal impairment. It is best not to take trimetazidine dihydrochloride during pregnancy. In case of lactation: Although there have been no reports of the excretion of trimetazidine in breast milk. However, patients should not breast-feed during treatment. Trimetazidine may cause or worsen Parkinson's disease. Therefore, patients (elderly) need to be checked and monitored regularly. In doubtful cases, the patient should be referred to a neurologist for appropriate examination. During the use of Vaspycar MR 35mg, patients encounter movement disorders such as: restless legs, tremors, unsteadiness, parkinsonian symptoms, ... the patient should immediately stop using the drug. These cases are usually very rare and will improve when the drug is stopped. In patients who are being treated with antihypertensive drugs, they may experience falls, low blood pressure, unsteady gait, .. When using Trimetazidine treatment may cause symptoms of dizziness and lethargy. Therefore, caution should be exercised when trimetazidine is used while driving or operating machinery. Keep Trimetazidine out of reach and reach of children. Patients should use the medicine according to the expiry date listed by the manufacturer printed on the box. The above article is useful information about the drug Vaspycar MR 35mg. When using, the drug should not be thrown into wastewater and domestic waste. Patients should ask their pharmacist or doctor before deciding to take the drug to ensure their own safety.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
